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66 Poster Session-Iresistance to immune control by APO2L/TRAIL in myeloma cells
by increasing synthesis of the anti-apoptotic protein c-FLIP, process
referred as environmental mediated-immune resistance (EM-IR) (J
Immunol, 180: 3; 2008). In this study we tested the hypothesis that
bortezomib may reverse APO2L/TRAIL EM-IR through its effects
on APO2L/TRAIL signaling pathways and/or related to modifica-
tions of stroma induced signals. To this end RPMI 8226 and U266
MM cells were treated adhered to HS5 stroma or exposed to HS5
in a transwell system. Pretreatment with bortezomib (10nM for 20
hours) not only induced synergistic cytotoxicity in myeloma but
did overcome TRAIL (10mg/mL for 4 hours) apoptosis resistance
induced by HS5 adhesion or HS5-released soluble factors. Mecha-
nistic studies showed that bortezomib is not cytotoxic to HS5 and
does not alter HS5 release of IL-6. Cytokine array testing showed
that stroma-myeloma co-culture lead to a significant increase in
IL-10 but bortezomib had no effect on IL-10 or other cytokines.
Bortezomib increased expression of TRAIL receptors (DR5,
DCR1 and DCR2), but such expression per se did not predict for
sensitivity to apoptosis. Factors released by HS5 stroma increased
expression of c-FLIP in myeloma cells, and bortezomib effectively
reduced c-FLIP. To determine whether the protection mediated
by stroma was directly linked to its ability to induce NF-kB, we
studied the activation of the transcription factor by a gel shift assay.
Bortezomib decreased NF-kB activation in MM without stroma but
was less effective in blocking it activation in the presence of stroma.
Because bortezomib abrogates cytokine-induce kinase activation
and understanding that c-FLIP may be under control of these
kinases, we next studied IL-6 signaling kinases. HS5-released
factor(s) induced STAT-3 and ERK phosphorylation but not AKT
activation, although bortezomib effects on c-FLIP shown to be inde-
pendent of these pathways. Our findings provide the rationale to
combine bortezomib to APO2L/TRAIL treatment to abrogate the
positive influence of the stroma microenvironment on myeloma
cell survival.177
STEM CELL MOBILIZATION IN PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA FOLLOWING THERAPY WITH LENALIDOMIDE
AND DEXAMETHASONE
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Miceli, T., Litzow, M.R., Rajkumar, S.V., Gertz, M.A. Mayo Clinic,
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Background: Lenalidomide based regimens appear to impact the
ability to harvest adequate number of stem cells for transplantation. In
order to identify factors predicting for poormobilization,we studied pa-
tients who underwent an attempt at stem cell mobilization after receiv-
ing lenalidomide and dexamethasone as primary therapy for myeloma.
Methods:We identified sequential patients (pts) who received le-
nalidomide and dexamethasone as initial therapy and then underwent
stem cell mobilization. Pts who received any other regimen prior to
the stem cell mobilization were excluded. Between July 2004 and
May 2008, 106 pts, satisfying the above criteria were identified.
Results: The median (range) age at mobilization was 60 yrs (29–
75); 34 (32%) were over 65 yrs. Themedian duration of lenalidomide
therapy was 4 mos (range; 1–13). The strategy for stem cell mobili-
zation was GCSF alone in 92 pts (87%), cyclophosphamide (CTX)
and GCSF in 11 pts and 3 pts received AMD3100 and GCSF.
Among the GCSF mobilized patients, 10 pts (11%) failed to collect
at least 2.5 million cells required for one transplant, including 8 pa-
tients who never achieved the minimum peripheral count threshold
to initiate the collection. Five of these pts subsequently underwent
successful salvage mobilization with CTX/GCSF, 1 with
AMD3100, one failed to mobilize with CTX and the rest did not re-
peat mobilization. Increasing patient age and the duration of lenali-
domide therapy, both correlated with decreasing 2-day CD34
collection, while the time between last dose of lenalidomide and
the start of GCSF had no effect. We then performed ROC analysis
to find best cut-off points that predicted the inability to collect ade-
quate (2.5 million) CD34 cells in 3 days. Lenalidomide therapy of
more than 4 months (P5 0.03) and age.63 yrs (P5 0.04) best pre-
dicted inability to achieve this endpoint. In addition, a peripheral
blood CD34 count\ 5/uL on day 5 after start of GCSF was highly
predictive of failure to reach this endpoint.Conclusions: Inability to collect adequate stem cells appears to be
related to pt age and duration of lenalidomide therapy. Patients
receiving more than 4 cycles of therapy and those over 65 years
should undergo mobilization with CTX1G-CSF, rather than
G-CSF alone. Majority of the pts who fail G-CSF based collection
can bemobilized using CTX andG-CSF. Early identification of fail-
ures using the peripheral CD34 counts can potentially allow salvage
using strategies such as AMD3100.178
TANDEM AUTOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC HEMA-
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RELATED OR UNRELATED DONORS FOR ADVANCED LYMPHOMA OR
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
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Thirty-three patients (pts) with advanced non-Hodgkin’s
lymphoma (67%), Hodgkin’s lymphoma (21%), or CLL (12%)
who were ineligible for ablative allogeneic HCT due to age and/or
comorbidities and were thought unlikely to have sustained response
following autograft alone were treated with tandem autologous
HCT followed, after a median of 65 days, by nonmyeloablative con-
ditioning and allograft. Allografts were either from HLA-matched
related (n 5 25) or unrelated donors (n 5 8). Median pt age was 49
years and number of prior regimens was 4 (range 1–12). Thirty-six
percent of pts had disease responsive to the last chemotherapy before
autografting [6% were in complete remission (CR)] while 46% and
18% had refractory and progressive disease, respectively. Most pts
had aggressive disease (82%). Conditioning for autografts consisted
of BEAM (48%) or Cy/12 Gy TBI (52%). At allografting, 52% of
pts hadCR/PR (15%/37%), 12% stable disease, 3% relapse, 33% re-
fractory disease. Nonmyeloablative conditioning for allografts con-
sisted of 2 Gy TBI alone (n 5 21) or with FLU (n 5 12), 90 mg/
m2. Pts received G-CSF mobilized PBMC. After allogeneic HCT,
24 pts became neutropenic for a median of 13 days and 23 pts had
thrombocytopenia (\20,000 cells/ul) for a median of 5 days. All 33
pts had sustained engraftment. Incidences of grades II, III, and IV
acute GVHD were 44%, 19%, and 0% respectively, and chronic
GVHD was 51%. Among 5 pts in CR at HCT, 4 are alive and in
CR and one died in CR. Among 12 in PR at HCT, 6 achieved CR
and are alive, one died in PR, and 5 had progression/relapse (1 is alive
inCR after chemoimmunotherapy andDLI).Of 4 pts with stable dis-
ease at HCT, all are alive, 3 in CR and one in CR after DLI and che-
moimmunotherapy.Among12 ptswith refractory/relapsed disease at
HCT, 5 achieved CR and are alive, 1 died in PR, and 6 relapsed (1 is
alive and inCR for 4 years followingRituximab).Withmedian follow
up of 39 (range 10–87) months, the overall response rate was 63%
(51% CR). Estimated 2-year rates of non-relapse mortality, relapse,
overall, and progression-free survivals from the time of autografting
were 16%, 38%, 55%, and 47% respectively. Histology, disease sta-
tus at autografting or allografting, donor type, conditioning regimens
for autografts, and time between autologous and allogeneic grafting
did not influence outcome. Tandem Auto-Allo HCT resulted in rel-
atively low NRM with median survival not yet reached among pts
with advanced lymphoma/CLL.outcomes by donor type
DonorRelated (n 5 25) Unrelated (n 5 8)% %Acute GVHD, grades II/ III/ IV at 120 days 33/25/0 75/0/0Chronic GVHD 47 63CR 49 572-year NRM 13 252-year progression/relapse 42 252-year PFS 46 502-year OS 57 50
